As part of its commitment to discovering and developing the highest
quality medical marijuana products, Cannabis Biotech’s scientific team
is exploring the benefits of terpenes. Cannabis Biotech is a subsidiary
of Puget Technologies (OTCBB:PUGE).
Terpenes are a large and diverse class of hydrocarbons produced by many
plants and are regularly encountered within the food chain as flavor and
fragrance agents.
In the cannabis plant, terpenes are responsible for delivering the
complex effects of the whole plant’s medicinal benefits and play a role
in its aroma and flavor.
Kenneth Morrow, prominent international marijuana authority and pioneer
in terpene research, is heading up Cannabis Biotech’s scientific team.
He said, “Terpenes are the most understudied component of the plant. We
do not have a great deal of information regarding terpenes and their
combined synergistic effect with the cannabinoids in marijuana.” He
added, “Through our research at Cannabis Biotech, we expect to learn
much about how terpenes can modulate and increase the medicinal effects
of cannabis and contribute to the industry’s body of scientific
knowledge.”
As previously announced, the company’s family of medical marijuana
products will begin with a metered-dose transmucosal delivery system, a
cannabis infused beverage line and transdermal patches.
This project is part of Cannabis Biotech’s strategy to enter the
multi-billion dollar medical marijuana industry by developing a wider
variety of delivery methods directed towards a growing, diverse patient
base. Cannabis Biotech’s research is focusing on the increasing number
of patients who desire the benefits of medical marijuana but do not want
the harmful effects or stigma of smoking it.
Currently 20 U.S. states and the District of Columbia have enacted laws
to legalize the use of medical marijuana.
Additional information about Cannabis Biotech can be found at http://www.cannabisbiotech.com.
About Puget Technologies (PUGE)
Puget Technologies is a publicly traded company on the OTCBB Market
stock exchange under the ticker symbol PUGE. Headquartered in Ft.
Lauderdale, Florida, Puget Technologies acquires, develops and sells
leading edge consumer oriented products ready for rapid
commercialization. Product lines under development include B-29 Energy
Drinks and several medical marijuana products through its subsidiary,
Cannabis Biotech. Puget’s strategy is to become a recognized market
leader in its product categories. Much of its resources are dedicated to
research and development in order to provide consumers with quality
options while meeting the expectations of its investors.
Safe Harbor Statement under the Private Securities Litigation
Reform Act of 1995: This news release contains forward-looking
information within the meaning of Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange act of
1934, as amended, including statements that include the words
"believes," "expects," "anticipates," or similar expressions. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results,
performance or achievements of the company to differ materially from
those expressed or implied by such forward looking statements. In
addition, description of anyone's past success, either financial or
strategic, is no guarantee of future success. This news release only
speaks as of the date of its distribution.
Copyright Business Wire 2013